Skip to content
MS
Sign in
unreviewed

N-acetyltransferase (NAT1/NAT2)

1 reactions · 1 pathways

Cofactors used

Acetyl-CoA

Clinical / pharmacological. Slow acetylators: isoniazid neuropathy, hydralazine/procainamide lupus

What it does, reaction by reaction

1 reactions

Phase II - Conjugation Xenobiotic & Drug Metabolism · Cytosol + ER

step 4 Irreversible/directional

Substrate + acetyl-CoA -> acetylated metabolite + CoA-SH

Converts Acetyl-CoA into Acetylated metabolite CoA-SH

› Notes

NAT2 slow-acetylator status predisposes to isoniazid neuropathy and hydralazine-induced lupus.

Showing all 1 reactions.

What accelerates and inhibits it

Regulation is pathway-specific, so each context is listed separately

0 entries

No regulation recorded for this enzyme in the source documents.

Recent literature

Refresh

Europe PMC · fetched just now · sorted by publication date

  1. 1
    Gut microbiota and diet in colorectal cancer: Converging determinants of carcinogenesis.

    Thakur BK, Choudhury SR, Turpin W, Martin A. · 2026-05-04

    cited 1× open access unreviewed
  2. 2
    Diagnosis, evaluation, and management of patients with non-muscle invasive bladder cancer.

    Manivasagam SS, Kassim A, Raman JD. · 2026-02-09

    open access unreviewed
  3. 3
    Cannabidiol lymphatic transport after oral administration assessed using a novel thoracic lymph duct cannulated conscious pig model.

    Rizov V, Lukáč P, Mlček M, Kozlík P, Křížek T, Jelínek P, Šodek P, Sklenárová M, Paulusová V, Symkanych O, St… · 2025-12-29

    open access unreviewed
  4. 4
    Reply to: Real-world safety signals of isoniazid in adults and children: a complementary FAERS analysis to inform paediatric dose optimisation

    Béranger A, Solans B, Savic R. · 2026-10-01

    open access unreviewed
  5. 5
    Safety and efficacy of a feed additive consisting of cocoa absolute from the dried seeds of Theobroma cacao L. in propylene glycol for use in all animal species except cats (FEFANA asbl)

    · 2026-10-01

    open access unreviewed
  6. 6
    Clinical Function Assignment of NAT2 Alleles by the Clinical Pharmacogenetics Implementation Consortium Pharmacogene Curation Expert Panel.

    Tibben BM, Hein DW, Whirl-Carrillo M, Gaedigk A, Eadon MT, Minchin RF, Boukouvala S, Santos AR, Donnelly RS, … · 2026-07-31

    cited 1× open access unreviewed
  7. 7
    Dosing and Safety of Once-Weekly Rifapentine and Isoniazid for 12 Weeks for Tuberculosis Preventive Therapy in Children With and Without HIV: Protocol for a Phase I/II Open-Label, Exposure-Controlled, Dose-Finding, and Safety Study (Tuberculosis Trials Consortium Study 35).

    Courtney I, Dixon MG, van der Laan L, Savic R, Solans B, Dooley K, Burton D, Barnabas S, Violari A, Bryant K,… · 2026-09-30

    open access unreviewed
  8. 8
    Analysis of NAT2 coding variants, combined genotypes, and haplotypes in prostate cancer susceptibility: a case-control study in an Iraqi Arab population.

    Tarish MA, Kudhair BK. · 2026-09-27

    unreviewed
  9. 9
    Mapping Pharmacogenomic Determinants of Adverse Drug Reactions in Hypertension: A Systematic Review.

    Dsouza VS, Kurian JR, Kalita M, Bora K, Phukan S, Das R, Bhowmick IP. · 2026-09-18

    open access unreviewed
  10. 10
    Special Issue "Molecular Biomarkers in Cancers: Advances and Challenges".

    Tappia PS, Ramjiawan B. · 2026-09-16

    open access unreviewed

External claims. These come from an index outside this database and are not checked against it. Treat them as leads.